Krystal Biotech

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2015-01-01

Employees: 229

Market Cap: $5.6B

Website: http://www.krystalbio.com

Introduction: Krystal Biotech, Inc. engages in developing and commercializing pharmaceutical products. It offers the product, VYJUVEK. The company was founded by Krish S. Krishnan and Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

Clinical Trials

A Study Assessing KB304 for the Treatment of Wrinkles in Women

Phase 1

Recruiting

Conditions: Wrinkles in Decolletage
Pigmentation
Décolleté Wrinkles

Interventions: Biological: KB304
Drug: 0.9% Normal Saline (NS)

First Posted Date: 2024-12-09

Last Posted Date: 2024-12-13

Lead Sponsor: Krystal Biotech, Inc.

Target Recruit Count: 21

Registration Number: NCT06724900

Locations: 🇺🇸
Steve Yoelin Medical Associates, Newport Beach, California, United States

A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)

Recruiting

Conditions: Epidermolysis Bullosa Dystrophica
Epidermolysis Bullosa Dystrophica, Recessive
Epidermolysis Bullosa Dystrophica Dominans

First Posted Date: 2024-08-20

Last Posted Date: 2024-08-21

Lead Sponsor: Krystal Biotech, Inc.

Target Recruit Count: 15

Registration Number: NCT06563414

Locations: 🇺🇸
Krystal Biotech, Pittsburgh, Pennsylvania, United States

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

Phase 1

Recruiting

Conditions: Lung Cancer, Non-small Cell
Lung Cancer Metastatic
Solid Tumor, Adult
Advanced Cancer
Lung Cancer (NSCLC)

Interventions: Biological: KB707
Drug: Pembrolizumab (KEYTRUDA®)
Drug: Chemotherapy

First Posted Date: 2024-01-29

Last Posted Date: 2024-11-14

Lead Sponsor: Krystal Biotech, Inc.

Target Recruit Count: 140

Registration Number: NCT06228326

Locations: 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸
IU Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Ochsner/MD Anderson Cancer Center, New Orleans, Louisiana, United States

and more 4 locations

A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency

Phase 1

Recruiting

Conditions: Alpha 1-Antitrypsin Deficiency

Interventions: Drug: KB408 (Nebulization)

First Posted Date: 2023-09-21

Last Posted Date: 2024-12-16

Lead Sponsor: Krystal Biotech, Inc.

Target Recruit Count: 12

Registration Number: NCT06049082

Locations: 🇺🇸
Renovatio Clinical, The Woodlands, Texas, United States
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Cancer
Melanoma Stage III
Melanoma Stage IV
Cutaneous Melanoma

Interventions: Biological: KB707
Drug: Opdualag

First Posted Date: 2023-08-01

Last Posted Date: 2024-11-14

Lead Sponsor: Krystal Biotech, Inc.

Target Recruit Count: 140

Registration Number: NCT05970497

Locations: 🇺🇸
UCLA Health, Los Angeles, California, United States
🇺🇸
Stanford Cancer Center, Palo Alto, California, United States
🇺🇸
Mission Dermatology Center, Rancho Santa Margarita, California, United States

and more 11 locations

Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

Phase 2

Not yet recruiting

Conditions: Autosomal Recessive Ichthyosis

Interventions: Other: Placebo
Biological: KB105

First Posted Date: 2023-02-21

Last Posted Date: 2023-02-23

Lead Sponsor: Krystal Biotech, Inc.

Target Recruit Count: 15

Registration Number: NCT05735158

Locations: 🇺🇸
Mission Dermatology, Rancho Santa Margarita, California, United States

A Study Assessing KB407 for the Treatment of Cystic Fibrosis

Phase 1

Recruiting

Conditions: Cystic Fibrosis

Interventions: Biological: KB407 (Nebulization)

First Posted Date: 2022-08-17

Last Posted Date: 2024-04-09

Lead Sponsor: Krystal Biotech, Inc.

Target Recruit Count: 12

Registration Number: NCT05504837

Locations: 🇺🇸
The Cystic Fibrosis Institute, Northfield, Illinois, United States
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis

Phase 1

Withdrawn

Conditions: Cystic Fibrosis

Interventions: Biological: KB407 (Nebulization)

First Posted Date: 2021-10-27

Last Posted Date: 2023-08-14

Lead Sponsor: Krystal Biotech, Inc.

Registration Number: NCT05095246

Locations: 🇦🇺
Hunter Medical Research Institute, Newcastle, New South Wales, Australia

Long-Term Follow-up Protocol

Recruiting

Conditions: Dystrophic Epidermolysis Bullosa
Dominant Dystrophic Epidermolysis Bullosa
Recessive Dystrophic Epidermolysis Bullosa

First Posted Date: 2021-06-08

Last Posted Date: 2021-06-08

Lead Sponsor: Krystal Biotech, Inc.

Target Recruit Count: 50

Registration Number: NCT04917887

Locations: 🇺🇸
Mission Dermatology Center, Rancho Santa Margarita, California, United States
🇺🇸
Pediatric Skin Research, Coral Gables, Florida, United States
🇺🇸
Stanford University, Redwood City, California, United States

A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa

Phase 3

Completed

Conditions: DEB - Dystrophic Epidermolysis Bullosa
Recessive Dystrophic Epidermolysis Bullosa
Dominant Dystrophic Epidermolysis Bullosa
Dystrophic Epidermolysis Bullosa

Interventions: Biological: Open Label Topical Beremagene Geperpavec (B-VEC)

First Posted Date: 2021-06-08

Last Posted Date: 2024-04-09

Lead Sponsor: Krystal Biotech, Inc.

Target Recruit Count: 47

Registration Number: NCT04917874

Locations: 🇺🇸
Mission Dermatology Center, Rancho Santa Margarita, California, United States
🇺🇸
Stanford University, Redwood City, California, United States
🇺🇸
Pediatric Skin Research, Coral Gables, Florida, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy